Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R21AA030372-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
After months of screening, we screened 175 individuals, only 3 were eligible, 2 declined, and 1 was moved to a different floor before study activities were able to take place.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | NIH |
Not provided
Not provided
Not provided
The investigators' approach is to conduct a pilot double-blind, placebo-controlled randomized clinical trial with individuals with alcohol use disorder (AUD) seeking inpatient alcohol detoxification in the emergency department (ED) to receive either intravenous ketamine or saline placebo. The primary aim is to evaluate the intervention's safety. The secondary aim is to evaluate the preliminary efficacy of alcohol-related outcomes.
This is a pilot double-blind, placebo-controlled randomized clinical trial of 50 individuals with alcohol use disorder (AUD) presenting to the emergency department (ED) seeking inpatient detoxification to receive either a single infusion of ketamine 0.8mg/kg (n=25) or saline placebo (n=25). The study will be conducted at Brigham and Women's Faulkner Hospital (BWF), an urban, 171-bed hospital located in Boston, MA, and a major teaching hospital for Harvard Medical School (HMS). Participants will be randomized in a double-blind fashion to receive either ketamine or saline placebo in the ED. All participants will receive the institution's standard treatment, which includes detoxification, intensive psychosocial support, and referral to outpatient treatment. The intervention (ketamine) will consist of a single infusion of ketamine in the ED at a dose of 0.8mg/kg over 40 minutes, and the placebo will be a 0.9% saline solution also administered over 40 minutes. To determine the safety of administering ketamine the investigators will measure the incidence of severe adverse events (AE), defined as either hypertensive urgency (systolic blood pressure>180mmHg or diastolic blood pressure>110mmHg) or tachycardia (heart rate>130bpm). The investigators will also assess side effects, alcohol withdrawal, and craving for alcohol and ketamine. To determine the preliminary efficacy of ketamine on alcohol-related outcomes, the investigators will measure the proportion of abstinent days during the follow-up assessed using Timeline Follow-Back (TLFB). The investigators will also measure days to relapse, the proportion of heavy drinking days, engagement with addiction treatment, urine ketamine, and alcohol biomarkers (urine ethylglucuronide and serum phosphatidylethanol) at 28-days. The investigators hypothesize that results will show adequate safety and that those receiving ketamine, compared to placebo, will not experience more side effects, worse withdrawal, or greater alcohol or ketamine craving. The investigators also hypothesize that those receiving ketamine will report better drinking outcomes compared to placebo.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ketamine | Experimental | This arm will receive ketamine (n=25) |
|
| Placebo | Placebo Comparator | This arm will receive the saline placebo (n=25) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ketamine | Drug | The intervention will consist of a single infusion of ketamine in the ED at a dose of 0.8mg/kg over 40 minutes. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety of administering ketamine in the emergency department (ED) for alcohol use disorder (AUD) patients seeking detoxification | The incidence of severe adverse events (AE), defined as either hypertensive urgency (systolic blood pressure>180mmHg or diastolic blood pressure>110mmHg) or tachycardia (heart rate>130bpm). Adequate safety will be defined as <10% of participants experiencing severe AEs. | Outcomes will be assessed throughout the inpatient admission, on average 3-5 days and throughout duration of study. |
| Measure | Description | Time Frame |
|---|---|---|
| Dissociative effects | Clinician-Administered Dissociative States Scale (CADSS) | Baseline, daily during inpatient (average 3-5 days), 28 days, and 3, 6, and 12 months after inpatient treatment. |
| Alcohol withdrawal |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Brigham and Women's Faulkner Hospital | Boston | Massachusetts | 02130 | United States |
Not provided
| ID | Term |
|---|---|
| D000437 | Alcoholism |
| ID | Term |
|---|---|
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D007649 | Ketamine |
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Saline | Drug | The placebo will be a 0.9% saline solution administered over 40 minutes. |
|
Clinical Institute Withdrawal Assessment (CIWA)
| Assessed during the inpatient admission, on average 3-5 days. |
| Craving for alcohol | Alcohol craving questionnaire | Assessed during the inpatient admission, on average 3-5 days; 7, 14, 28 days and 3, 6, and 12 months after treatment |
| Craving for ketamine | Visual analog scale | Assessed during the inpatient admission, on average 3-5 days; 7, 14, 28 days and 3, 6, and 12 months after treatment |
| Cue-induced craving | Visual analog scale will be used to rate the craving following a standardized protocol used to assess cue reactivity. The cue exposure procedure will end with a standardized relaxation exercise. | Assessed during the inpatient admission, on average 3-5 days; 28 days after treatment |
| Preliminary efficacy of ketamine on days to alcohol relapse | Days to relapse will be measured by using the Timeline Follow-Back (TLFB). | 7, 14, 28 days and 3, 6, and 12 months after treatment |
| Preliminary efficacy of ketamine on proportion heavy drinking days | The proportion of heavy drinking days will be measured by using the Timeline Follow-Back (TLFB). | 7, 14, 28 days and 3, 6, and 12 months after treatment |
| Preliminary efficacy of ketamine on engagement with addiction treatment | The Alcoholic Anonymous Affiliation Scale (AAAS) will be used to measure engagement with addiction treatment. This is a 9-item scale to measure the degree of involvement with Alcoholics Anonymous. | Measured at baseline, 28 days, and 3, 6, and 12 months post treatment. |
| Ketamine in Urine | Urine drug screen that includes ketamine will be assessed. | At baseline and 28 days after treatment |
| Urine ethylglucuronide | Urine ethylglucuronide (EtG) will be obtained | At baseline and at 28 days after treatment |
| Phosphatidylethanol (PEth) | Serum phosphatidylethanol (PEth) | At baseline and at 28 days after treatment |
| Behavior Change Mechanisms | Mechanisms of behavior change will be measured using tools from the Science of Behavior Change Measures. | Once during inpatient treatment and at 28 days after treatment |
| Anxiety | We will assess anxiety levels utilizing a 7-item scale (Generalized Anxiety Disorder - 7 (GAD-7)) | At baseline, each day during treatment (3-5 Days on average), 7, 14, 28 days and 3, 6, and 12 months after treatment |
| Depression | We will assess depression levels utilizing a 9-item scale (Patient Health Questionnaire-9 (PHQ-9)) | At baseline, each day during treatment (3-5 Days on average), 7, 14, 28 days and 3, 6, and 12 months after treatment |
| Suicidal Ideation | Columbia Suicide Severity Rating Scale (C-SSRS) will be used to assess suicidal Ideation | At baseline, each day during treatment (3-5 Days on average), 7, 14, 28 days and 3, 6, and 12 months after treatment |
| Post Traumatic Stress | A patient self-report tool developed to examine PTSD symptoms in general medical settings (Abbreviated PTSD Checklist - Civilian Version) | Once during treatment |
| Study Drug Side Effects | We will use Patient Rated Inventory of Side Effects (PRISE) to qualify side effects in the following domains: gastrointestinal, heart, skin, nervous system, eyes/ears, genital/urinary, sleep, sexual functioning, and other. Each domain has multiple symptoms which can be endorsed. For each domain the patient rates whether the symptoms are tolerable or distressing. | At baseline, each day during treatment (3-5 Days on average), 7, 14, 28 days and 3, 6, and 12 months after treatment |
| Spirituality | We will use a 23-item measure to assess spirituality (Spirituality Scale). | Baseline, once during treatment, and at 28 days post treatment. |
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017670 | Sodium Compounds |